Target intelligence / Profile preview

RalA-binding protein 1 (RALBP1)

Target
RALBP1
Molecular classification
Enzyme, Transporter, GTPase-activating protein, Scaffold protein
01

Overview

RalA-binding protein 1 (RALBP1) is a multifunctional effector protein acting downstream of the small GTPases RALA and RALB[1][2][6]. It integrates Ras and Rho family signalling by serving as both a GTPase-activating protein (GAP) for Rho family members (such as CDC42 and RAC1) and a scaffold protein facilitating mitosis-specific kinase signaling[1][2]. RALBP1 plays essential roles in receptor-mediated endocytosis, cell migration, mitochondrial fission, and in mediating the cellular response to metabolites and toxins by active ATP-dependent transport of glutathione conjugates and xenobiotics, including chemotherapeutic agents like doxorubicin[2][6]. Overexpression or dysregulation of RALBP1 is linked to cancer cell survival, multidrug resistance, and potentially tumor progression[2][3].

Other names
RLIPRLIP1RLIP76RalBP1DNP-SG ATPaseRIP1RIP76 kDa Ral-interacting proteinDinitrophenyl S-glutathione ATPaseral-interacting protein 1
02

Mechanism of action

ATP-dependent transporter activity for glutathione conjugates and xenobiotics, GTPase-activating activity (GAP) for CDC42 and RAC1, scaffold for kinase-mediated phosphorylation events during mitosis

03

Biological functions

Signal transductionReceptor-mediated endocytosisCell migrationMitochondrial divisionMetabolite transportMultidrug resistanceScaffold activity during mitosis
04

Disease associations

Cancer (notably lung cancer and lung non-small cell carcinoma)Multidrug resistance in cancerOther (possible implication in cell proliferation and cell migration disorders)
05

Safety considerations

Contribution to multidrug resistance can limit efficacy of chemotherapeuticstargeting may affect normal endocytosis, cell migration, or mitochondrial dynamics
06

Interacting drugs

doxorubicin (noted as a substrate)

1 more in the full profile.

07

Biomarkers

Increased expression associated with multidrug resistance in cancer cellspotential biomarker in cancer, especially for drug resistance

Beyond the preview

Go deeper on RalA-binding protein 1 (RALBP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RalA-binding protein 1 (RALBP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call